Last reviewed · How we verify
Levobupivacaine Hydrochloride 0.25 % Injectable Solution — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Levobupivacaine Hydrochloride 0.25 % Injectable Solution (Levobupivacaine Hydrochloride 0.25 % Injectable Solution) — Algemeen Ziekenhuis Maria Middelares.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Levobupivacaine Hydrochloride 0.25 % Injectable Solution TARGET | Levobupivacaine Hydrochloride 0.25 % Injectable Solution | Algemeen Ziekenhuis Maria Middelares | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Levobupivacaine Hydrochloride 0.25 % Injectable Solution CI watch — RSS
- Levobupivacaine Hydrochloride 0.25 % Injectable Solution CI watch — Atom
- Levobupivacaine Hydrochloride 0.25 % Injectable Solution CI watch — JSON
- Levobupivacaine Hydrochloride 0.25 % Injectable Solution alone — RSS
Cite this brief
Drug Landscape (2026). Levobupivacaine Hydrochloride 0.25 % Injectable Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/levobupivacaine-hydrochloride-0-25-injectable-solution. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab